Literature DB >> 24045500

Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

M Bhutani1, B Turkbey2, E Tan1, T J Kemp3, L A Pinto3, A R Berg1, N Korde1, A R Minter1, B M Weiss1, E Mena2, L Lindenberg2, O Aras2, M P Purdue4, J N Hofmann4, S M Steinberg5, K R Calvo6, P L Choyke2, I Maric6, K Kurdziel2, O Landgren1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24045500      PMCID： PMC6896984          DOI： 10.1038/leu.2013.268

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 2.  Bone marrow angiogenesis in patients with active multiple myeloma.

Authors:  A Vacca; D Ribatti; A M Roccaro; A Frigeri; F Dammacco
Journal:  Semin Oncol       Date:  2001-12       Impact factor: 4.929

Review 3.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

Review 4.  Bone marrow angiogenesis in multiple myeloma.

Authors:  A Vacca; D Ribatti
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

5.  Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Authors:  Niels Frost Andersen; Therese Standal; Johan Lanng Nielsen; Lene Heickendorff; Magne Borset; Flemming Brandt Sørensen; Niels Abildgaard
Journal:  Br J Haematol       Date:  2005-01       Impact factor: 6.998

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].

Authors:  K Wasser; T Moehler; K Neben; S Nosas; J Heiss; H Goldschmidt; J Hillengass; C Düber; H U Kauczor; S Delorme
Journal:  Rofo       Date:  2004-09

8.  Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

Authors:  M Teresa Cibeira; María Rozman; Marta Segarra; Esther Lozano; Laura Rosiñol; Maria C Cid; Xavier Filella; Joan Bladé
Journal:  Cytokine       Date:  2008-01-04       Impact factor: 3.861

9.  Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.

Authors:  Michael A Thompson; Thomas E Witzig; Shaji Kumar; Michael M Timm; Jessica Haug; Rafael Fonseca; Philip R Greipp; John A Lust; S Vincent Rajkumar
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813
View more
  11 in total

1.  [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].

Authors:  M Bhutani; O Landgren
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

2.  Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Authors:  Manisha Bhutani; Baris Turkbey; Esther Tan; Neha Korde; Mary Kwok; Elisabet E Manasanch; Nishant Tageja; Sham Mailankody; Mark Roschewski; Marcia Mulquin; Ashley Carpenter; Elizabeth Lamping; Alex R Minter; Brendan M Weiss; Esther Mena; Liza Lindenberg; Katherine R Calvo; Irina Maric; Saad Z Usmani; Peter L Choyke; Karen Kurdziel; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2016-04-07

3.  Targeting vasculogenesis to prevent progression in multiple myeloma.

Authors:  M Moschetta; Y Mishima; Y Kawano; S Manier; B Paiva; L Palomera; Y Aljawai; A Calcinotto; C Unitt; I Sahin; A Sacco; S Glavey; J Shi; M R Reagan; F Prosper; M Bellone; M Chesi; L P Bergsagel; A Vacca; A M Roccaro; I M Ghobrial
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

4.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

5.  Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Authors:  Maximilian Merz; Thomas M Moehler; Judith Ritsch; Tobias Bäuerle; Christian M Zechmann; Barbara Wagner; Anna Jauch; Dirk Hose; Christina Kunz; Thomas Hielscher; Hendrik Laue; Hartmut Goldschmidt; Stefan Delorme; Jens Hillengass
Journal:  Eur Radiol       Date:  2015-07-29       Impact factor: 5.315

Review 6.  New Approaches to Molecular Imaging of Multiple Myeloma.

Authors:  Ravi Vij; Kathryn J Fowler; Monica Shokeen
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

7.  A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor.

Authors:  Jonathan N Hofmann; Ola Landgren; Rebecca Landy; Troy J Kemp; Loredana Santo; Charlene M McShane; Joseph J Shearer; Qing Lan; Nathaniel Rothman; Ligia A Pinto; Ruth M Pfeiffer; Allan Hildesheim; Hormuzd A Katki; Mark P Purdue
Journal:  JNCI Cancer Spectr       Date:  2019-12-16

8.  Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.

Authors:  Arianna Calcinotto; Maurilio Ponzoni; Roberto Ria; Matteo Grioni; Elena Cattaneo; Isabella Villa; Maria Teresa Sabrina Bertilaccio; Marta Chesi; Alessandro Rubinacci; Giovanni Tonon; P Leif Bergsagel; Angelo Vacca; Matteo Bellone
Journal:  Oncoimmunology       Date:  2015-05-07       Impact factor: 8.110

9.  Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells.

Authors:  Fei Wang; Wei Zhang; Liting Guo; Wen Bao; Nan Jin; Ran Liu; Ping Liu; Yonghui Wang; Qinglong Guo; Baoan Chen
Journal:  Cancer Sci       Date:  2014-07-27       Impact factor: 6.716

Review 10.  The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Authors:  Liesbeth Bieghs; Hans E Johnsen; Ken Maes; Eline Menu; Els Van Valckenborgh; Michael T Overgaard; Mette Nyegaard; Cheryl A Conover; Karin Vanderkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.